These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...

What's the most attractive weight-loss stock right now? We asked Seeking Alpha analysts Edmund Ingham, Stephen Ayers and Oneil Trader for their picks. Read more here.

Donald Trump is executing a shock-and-awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ending birthright citizenship, are quickly slapped down in the courts. Some, ...

Jim Cramer, the host of Mad Money, discussed the upcoming market and corporate activity to look forward to this week, which ...

Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ending birthright citizenship, are quickly slapped down in the courts. Some, ...

The right-wing argues, as Project 2025 puts it, that government negotiations on Medicare drugs amount to “price controls” that will reduce patient access to new medication. That’s news to the citizens ...

Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ...

A couple of months ago, healthcare equity research analyst Jared Holz from Mizuho spoke about Viking potentially being an acquisition target. During his discussion, Holz suggested that Viking could ...

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular ...

More than half of adults with overweight or obesity prescribed a GLP-1 discontinue their drug within 1 year, with discontinuation rates higher for those without type 2 diabetes, researchers reported ...

While the former Biden administration showcased the Inflation Reduction Act as a key victory in the fight over high drug ...